Profound Medical Corp. (PROF) |
| 6.85 -0.11 (-1.58%) 08-28 16:00 |
| Open: | 6.86 |
| High: | 6.89 |
| Low: | 6.84 |
| Volume: | 18,183 |
| Market Cap: | 249(M) |
| PE Ratio: | -6.99 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 8.50 |
| Resistance 1: | 7.74 |
| Pivot price: | 6.88 |
| Support 1: | 6.51 |
| Support 2: | 5.42 |
| 52w High: | 8.95 |
| 52w Low: | 3.76 |
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
| EPS | -0.990 |
| Book Value | 1.630 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.375 |
| Profit Margin (%) | -171.56 |
| Operating Margin (%) | -445.67 |
| Return on Assets (ttm) | -39.5 |
| Return on Equity (ttm) | -73.5 |
Mon, 17 Aug 2026
Profound Medical (NASDAQ: PROF) targets higher TULSA throughput - Stock Titan
Fri, 14 Aug 2026
Profound Medical Announces Management Change - Yahoo Finance
Thu, 13 Aug 2026
A prostate cancer survivor helps men navigate care through Let's Huddle - Stock Titan
Thu, 13 Aug 2026
Profound Medical (PROF) launches global ‘Let’s Huddle’ prostate patient community - Stock Titan
Thu, 06 Aug 2026
About $3.1M of Profound shipments will count as Q3 revenue - Stock Titan
Wed, 05 Aug 2026
Earnings To Watch: Profound Medical Corp (PROF) Q2 2026 -- GF Value Sees 226% Upside - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |